Treatment of Ureaplasma Infection
Critical Evidence Gap and Recommendation
Routine testing and treatment of Ureaplasma urealyticum and Ureaplasma parvum are NOT recommended in asymptomatic or symptomatic men and women, including pregnant patients, according to the European STI Guidelines Editorial Board. 1
The provided evidence contains no guidelines specifically addressing Ureaplasma treatment—all guideline documents discuss unrelated conditions (toxoplasmosis, febrile infants, Lyme disease, and urinary tract infections). The only relevant evidence comes from research studies and position statements.
Evidence-Based Position
General Population (Non-Pregnant)
Asymptomatic carriage of Ureaplasma is common (40-80% of detected cases) and the majority of individuals do not develop disease, making routine screening and treatment potentially harmful rather than beneficial. 1
Testing should only be considered in men with symptomatic urethritis after excluding traditional STI agents (Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis), and only if quantitative species-specific molecular tests demonstrate high U. urealyticum load. 1
In symptomatic women, bacterial vaginosis should always be tested for and treated first before considering Ureaplasma as a causative agent. 1
Pregnancy and Lactation
No specific guidelines exist for treating confirmed Ureaplasma in pregnant or lactating patients, and the European STI Guidelines Editorial Board position against routine testing applies equally to pregnancy. 1
Ureaplasma species are commonly found as commensals on the lower urogenital tract mucosa of pregnant women, and their presence does not automatically warrant treatment. 2
When ascending infection occurs, Ureaplasma can cause chorioamnionitis, premature birth, and neonatal complications (bronchopulmonary dysplasia, early-onset sepsis), but current empiric antibiotic treatment in neonates is not directed against Ureaplasma. 2
Treatment Regimens (When Treatment Is Pursued)
First-Line Options
Azithromycin 1 g single dose was effective in eliminating Ureaplasma in women with chronic urinary symptoms, with mean symptom severity improving from 2.2 to 0.7 (P <0.001). 3
For persistent infection after azithromycin, 7-day courses of doxycycline, ofloxacin, or erythromycin were used successfully. 3
Antimicrobial Susceptibility Data
Rokitamycin and midecamycin acetate demonstrate highest activity (MIC90 ≤0.05 μg/mL), followed by erythromycin, josamycin, doxycycline, minocycline, and tetracycline (MIC90 0.1-0.78 μg/mL). 4
Tetracycline resistance occurs in 5% of strains, with 2% resistant to minocycline and doxycycline, though all remained susceptible to newer macrolides. 4
Resistance to macrolides, tetracyclines, and fluoroquinolones has been reported, with susceptibility patterns varying between biovars. 5
Critical Caveats
Extensive testing and treatment may select for antimicrobial resistance in Ureaplasma, true STI agents, and general microbiota, creating substantial economic cost without proven benefit. 1
Commercialized multiplex PCR assays detecting Ureaplasma alongside traditional STIs have worsened inappropriate testing and treatment, leading to overdiagnosis of colonization rather than true infection. 1
Detection is challenging and not covered by routine diagnostics; culture and PCR are the mainstay, but interpretation requires clinical correlation. 5, 2
Pregnancy-Specific Considerations
If treatment is pursued in pregnancy despite lack of guideline support:
Azithromycin is generally considered safe in pregnancy and was the initial agent used in the only treatment study available. 3
Doxycycline should be avoided in pregnancy due to effects on fetal bone and teeth development (general medical knowledge, not cited in provided evidence).
Erythromycin is pregnancy-compatible and was used as an alternative in the treatment study. 3
No evidence supports routine post-treatment testing or surveillance cultures in asymptomatic patients. 1